Post-Market Surveillance of Six COVID-19 Point-of-Care Tests Using

2 Pre-Omicron and Omicron SARS-CoV-2 Variants

- 3 Running Title: PMS of COVID-19 POCT using SARS-CoV-2 Variants
- 4
- 5 Hannah M. Exner^a, Branden S. J. Gregorchuk^a, AC-Green Castor^a, Leandro Crisostomo^a, Kurt
- 6 Kolsun^b, Shayna Giesbrecht^b, Kerry Dust^c, David Alexander^c, Ayooluwa Bolaji^c, Zoe Quill^a,
- 7 Breanne M. Head^a, Adrienne F. A. Meyers^d, Paul Sandstrom^{a,e}, Michael G. Becker^{a,b,*}
- ⁸ ^aJC Wilt Infectious Diseases Research Centre, National Microbiology Laboratory Branch, Public
- 9 Health Agency of Canada, Winnipeg, Manitoba, Canada
- ¹⁰ ^bDepartment of Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
- ¹¹ ^cCadham Provincial Laboratory, Winnipeg, Manitoba, Canada
- ¹² ^dOffice of Population and Public Health, Indigenous Services Canada, Ottawa, Ontario, Canada
- ¹³ ^eDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg,
- 14 Manitoba, Canada
- 15
- ¹⁶ *Address correspondence to Michael Becker, Michael.Glen.Becker@phac-aspc.gc.ca
- 17

18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		

38 ABSTRACT

Post-market surveillance of test performance is a critical function of public health 39 agencies and clinical researchers that ensures diagnostics maintain performance characteristics 40 following their regulatory approval. Changes in product quality, manufacturing processes over 41 time, or the evolution of new variants may impact product quality. During the COVID-19 42 pandemic, a plethora of point-of-care tests (POCTs) were released onto the Canadian market. 43 This study evaluated the performance characteristics of several of the most widely-distributed 44 POCTs in Canada, including four rapid antigen tests (Abbott Panbio, BTNX Rapid Response, SD 45 Biosensor, Quidel QuickVue) and two molecular tests (Abbott ID NOW, Lucira Check IT). All tests 46 were challenged with 149 SARS-CoV-2 clinical positives, including multiple variants up to and 47 including Omicron XBB.1.5, as well as 29 clinical negatives. Results were stratified based on 48 whether the isolate was Omicron or pre-Omicron as well as by RT-qPCR Ct value. The test 49 performance of each POCT was consistent with the manufacturers' claims and showed no 50 significant decline in clinical performance against any of the variants tested. These findings 51 provide continued confidence in the results of these POCTs as they continue to be used to 52 support decentralized COVID-19 testing. This work demonstrates the essential role of post-53 market surveillance in ensuring reliability in diagnostic tools. 54

- 55
- 56
- 57

58

59

60 INTRODUCTION

During the COVID-19 pandemic, it became clear that an effective public health response 61 required rapid and widespread testing for SARS-CoV-2. Although testing initially relied on 62 laboratory-based reverse transcriptase quantitative PCR (RT-qPCR), decentralized testing quickly 63 became the preferred screening method (1, 2) facilitated through the use of point-of-care tests 64 (POCTs). This shift was accelerated following the emergence of the highly transmissible Omicron 65 variant (Pango lineage B.1.1.529) in December 2021 (3-5) causing unprecedented testing 66 demand that overwhelmed centralized testing facilities (4-6). As of August 2023, 55 POCTs have 67 been authorized for use in Canada through the "Interim order respecting the importation and 68 sale of medical devices for use in relation to COVID-19" (7). These devices can be broadly 69 categorized into two groups: molecular tests and rapid antigen detection tests (RADTs). 70 Molecular POCTs detect the presence of SARS-CoV-2-specific nucleic acid sequences through PCR 71 or isothermic amplification techniques such as loop-mediated isothermal amplification (LAMP) 72 (1, 8, 9). Molecular tests generally provide a high level of sensitivity and may detect viral RNA 73 weeks after infection (9-11). In comparison, RADTs detect SARS-CoV-2 surface proteins with 74 decreased sensitivity, particularly when considering asymptomatic cases with lower viral loads 75 (12-14).76

Post-market surveillance monitors the performance of POCTs following commercialization and distribution as well as provides independent investigations that assess the manufacturers' claims regarding test efficacy in real-world settings (15). Ongoing monitoring becomes exceedingly important for POCTs as few quality controls are in place compared to

clinical testing performed in centralized test facilities. Test performance may also deviate over time due to changes in manufacturing materials or processes (16, 17), or through viral evolution of test targets. For molecular POCTs, test performance may be impacted by base substitutions at the primer binding sites, which can often be predicted *in silico (18)*. RADT performance may also be impacted by mutations within target proteins, however, predicting this computationally is more challenging as it is influenced by protein 3D structure. Therefore, post-market surveillance of RADTs relies more heavily on experimentation.

Initial studies evaluating the performance of various RADTs found reduced impaired detection of Omicron variants compared to previously circulating strains (19-21). For example, Osterman et al. reported that multiple RADTs tested had 101-fold lower sensitivity against Omicron BA.1 compared to Delta (21). Although this study may raise concerns surrounding the continued use of these RADTs, multiple subsequent studies demonstrated equivalent sensitivity regardless of variant (22-24). Together, this emphasizes the need to disseminate negative test results in post-market surveillance studies.

Due to the variety of POCTs available globally, tests evaluated in published research often have little to no overlap with the POCTs widely distributed in Canada. Although manufacturers may provide post-market surveillance data regarding performance, these may be based heavily on *in silico* analyses and experimental results may differ (25). Therefore, there is a need for regulatory bodies, clinicians, and public health officials to conduct ongoing aftermarket evaluations and to effectively communicate the results to POCT users. Accordingly, the aim of this post-market surveillance study was to assess the analytical performance of six widely

distributed POCTs and to determine if there were differences in the detection of pre-Omicron
 and Omicron variants.

104 MATERIALS AND METHODS

SARS-CoV-2 positive and negative patient samples were used to determine the sensitivity, 105 specificity, and experimental limit of detection (LoD) of each of the COVID-19 POCTs. Clinical 106 samples, reference cycle thresholds (Ct), and lineage data were provided by Cadham Provincial 107 Laboratory (CPL; Manitoba, Canada). Reference Ct values were characterized on remnant 108 universal transport media (UTM) from 149 SARS-CoV-2 positive and 29 negative nasopharyngeal 109 swabs using the Roche 6800 Cobas SARS-CoV-2 test targeting the Open Reading Frame 1a and 110 Envelope genes. Samples were then categorized based on lineage into pre-Omicron (Alpha 111 [B.1.1.7], Delta [B.1.617.2]) or Omicron (BA.1, BA.2, BA.4, BA.5, or XBB.1.5) groups (Table 1). For 112 samples for which lineage data was not available (collected before routine sequencing), lineage 113 was predicted based on the sampling date. No ethics were required under Article 2.4 and Article 114 2.5 of the Tri-Council Policy Statement Ethical Conduct for Research Involving Humans (26) as 115 these were remnant clinical specimens used for assay validation. To minimize sample 116 degradation, each sample was limited to a maximum of two freeze-thaw cycles. 117

118

119

SARS-CoV-2 Lineage	Number of Samples
Alpha	40
Delta/Kappa	15
Omicron BA.1	25
Omicron BA.2	15
Omicron BA.4	10
Omicron BA.5	23
Omicron XBB.1.5	21

121	TABLE 1. Lineage of	f SARS-CoV-2 pc	ositive clinical	l samples i	used in the study.

Six Health Canada-approved COVID-19 POCTs were evaluated in this study; four RADTs
 including the BTNX Rapid Response[®] COVID-19 Antigen Rapid Test (BTNX Inc., Canada), the
 Abbott Panbio[™] COVID-19 Ag Rapid Test Device (Abbott Rapid Diagnostics Jena Gmbh, Germany),
 the SD Biosensor COVID-19 Ag Test (SD Biosensor Inc., South Korea) and the Quidel QuickVue[®]
 At-Home OTC COVID-19 Test (Quidel Corporation, United States); as well as two LAMP-based
 molecular tests: the Abbott ID NOW[™] COVID-19 Assay (Abbott Diagnostics Scarborough, Inc.,
 United States) and the Lucira[™] Check IT COVID-19 Test Kit (Lucira Health, Inc., United States).

For each POCT, 10 μL of remnant UTM was transferred directly into the assay buffer and subsequently mixed with the manufacturer-provided swab. Each test was then performed according to the manufacturer's instructions. For RADT results that required visual interpretation, test strips were read independently by three technicians and the consensus was reported. If necessary, invalid tests were repeated until a positive or negative result was encountered.

Data were analyzed using R version 4.2.1 software. Sample Ct values were adjusted to account for the quantity of virus input into the device corresponding to the concentration when eluted into a 3 mL volume. Continuous variables such as Ct are represented as medians and

138	interquartile ranges (IQR). Categorical variables, such as sensitivity and specificity, are reported
139	as percentages with 95% confidence intervals (95% CI) calculated using the Wilson score method.
140	Sensitivity was also determined for each POCT when samples were stratified based on a Ct of \leq
141	30 and > 30, i.e., the acceptable LoD outlined by the World Health Organization (WHO) for RADTs
142	(27) and the cut-off typically used in clinical settings and other evaluations (2, 16, 28). For each
143	POCT, the overall and stratified sensitivity values were compared between the pre-Omicron and
144	Omicron groups using a two-tailed Fisher's Exact Test with an α of 0.05.

Next, based on the guidelines recommended by the Clinical & Laboratory Standards Institute (29), a probit model was constructed for each assay to determine the 95% LoD, representing the estimated concentration at which 95% of positive samples are successfully identified. The 95% CI for each LoD was calculated using the Wald method, then the LoDs were compared between Pre-Omicron and Omicron to determine if the analytical sensitivity of each POCT differed by variant.

151 **RESULTS**

152 Performance Characteristics of POCTs with Pre-Omicron and Omicron Variants

A total of 149 SARS-CoV-2 clinical positives with a median Ct value of 30.2 (IQR 26.8–33.8) and 29 SARS-CoV-2 clinical negatives were tested using all six POCTs. Of the positive samples, 94 were determined to be Omicron subvariants (median Ct value 29.7; IQR 27.1–33.5) and the remaining 55 were identified as pre-Omicron (median Ct value 30.0; IQR 26.0–34.4). No false

138invalid results were obtained during the study: two with the ID NOW and one with the159Overall sensitivity of RADTs ranged from 46-65% compared to 86-98.9% for160tests (Table 2). For all tests, sensitivity was similar between Omicron compared to p161samples when analyzing all Ct values together. Similarly, when stratifying test results162tests, no significant difference in sensitivity was observed between pre-Omicron a163samples with high viral loads (i.e., Ct \leq 30; Table 2). At low viral loads (i.e., Ct $>$ 30164differences in ID NOW (p = 0.021) and QuickVue (p = 0.028) sensitivity was observed165pre-Omicron and Omicron variants.166Limit of Detection Analysis of POCTs With All Variants167Probit regression analyses was performed using data from all 149 SARS-Ct168specimens to determine the 95% LoD of each test (Fig. 1). The molecular POCTs, the169Check IT, had 95% LoDs of 34.7 and 39.3 Ct values, respectively, highlighting their abil170low quantities of virus. RADTs had 95% LoDs ranging between 25.0 to 28.4 (Table A1171172	oss all tests. Three
160tests (Table 2). For all tests, sensitivity was similar between Omicron compared to p161samples when analyzing all Ct values together. Similarly, when stratifying test results162tests, no significant difference in sensitivity was observed between pre-Omicron a163samples with high viral loads (i.e., $Ct \le 30$; Table 2). At low viral loads (i.e., $Ct > 30$ 164differences in ID NOW (p = 0.021) and QuickVue (p = 0.028) sensitivity was observed165pre-Omicron and Omicron variants.166 <i>Limit of Detection Analysis of POCTs With All Variants</i> 167Probit regression analyses was performed using data from all 149 SARS-Co168specimens to determine the 95% LoD of each test (Fig. 1). The molecular POCTs, the169Check IT, had 95% LoDs of 34.7 and 39.3 Ct values, respectively, highlighting their abil170low quantities of virus. RADTs had 95% LoDs ranging between 25.0 to 28.4 (Table A1171172	vith the Check IT.
161samples when analyzing all Ct values together. Similarly, when stratifying test results162tests, no significant difference in sensitivity was observed between pre-Omicron a163samples with high viral loads (i.e., Ct \leq 30; Table 2). At low viral loads (i.e., Ct $>$ 30164differences in ID NOW (p = 0.021) and QuickVue (p = 0.028) sensitivity was observe165pre-Omicron and Omicron variants.166 <i>Limit of Detection Analysis of POCTs With All Variants</i> 167Probit regression analyses was performed using data from all 149 SARS-Co168specimens to determine the 95% LoD of each test (Fig. 1). The molecular POCTs, the169Check IT, had 95% LoDs of 34.7 and 39.3 Ct values, respectively, highlighting their abil170low quantities of virus. RADTs had 95% LoDs ranging between 25.0 to 28.4 (Table A1171172	9% for molecular
162tests, no significant difference in sensitivity was observed between pre-Omicron a163samples with high viral loads (i.e., $Ct \le 30$; Table 2). At low viral loads (i.e., $Ct > 30$ 164differences in ID NOW (p = 0.021) and QuickVue (p = 0.028) sensitivity was observ165pre-Omicron and Omicron variants.166 <i>Limit of Detection Analysis of POCTs With All Variants</i> 167Probit regression analyses was performed using data from all 149 SARS-Co168specimens to determine the 95% LoD of each test (Fig. 1). The molecular POCTs, the169Check IT, had 95% LoDs of 34.7 and 39.3 Ct values, respectively, highlighting their abil170low quantities of virus. RADTs had 95% LoDs ranging between 25.0 to 28.4 (Table A1	d to pre-Omicron
 samples with high viral loads (i.e., Ct ≤ 30; Table 2). At low viral loads (i.e., Ct > 30 differences in ID NOW (p = 0.021) and QuickVue (p = 0.028) sensitivity was observ pre-Omicron and Omicron variants. <i>Limit of Detection Analysis of POCTs With All Variants</i> Probit regression analyses was performed using data from all 149 SARS-Co specimens to determine the 95% LoD of each test (Fig. 1). The molecular POCTs, the Check IT, had 95% LoDs of 34.7 and 39.3 Ct values, respectively, highlighting their abil low quantities of virus. RADTs had 95% LoDs ranging between 25.0 to 28.4 (Table A1 	esults by Ct for all
 differences in ID NOW (p = 0.021) and QuickVue (p = 0.028) sensitivity was observer pre-Omicron and Omicron variants. <i>Limit of Detection Analysis of POCTs With All Variants</i> Probit regression analyses was performed using data from all 149 SARS-Corspectiments to determine the 95% LoD of each test (Fig. 1). The molecular POCTs, the Check IT, had 95% LoDs of 34.7 and 39.3 Ct values, respectively, highlighting their abil low quantities of virus. RADTs had 95% LoDs ranging between 25.0 to 28.4 (Table A1 	ron and Omicron
 pre-Omicron and Omicron variants. <i>Limit of Detection Analysis of POCTs With All Variants</i> Probit regression analyses was performed using data from all 149 SARS-Co specimens to determine the 95% LoD of each test (Fig. 1). The molecular POCTs, the Check IT, had 95% LoDs of 34.7 and 39.3 Ct values, respectively, highlighting their abil low quantities of virus. RADTs had 95% LoDs ranging between 25.0 to 28.4 (Table A1 	> 30), significant
Limit of Detection Analysis of POCTs With All Variants Probit regression analyses was performed using data from all 149 SARS-Co specimens to determine the 95% LoD of each test (Fig. 1). The molecular POCTs, the Check IT, had 95% LoDs of 34.7 and 39.3 Ct values, respectively, highlighting their abil low quantities of virus. RADTs had 95% LoDs ranging between 25.0 to 28.4 (Table A1 171	oserved between
Probit regression analyses was performed using data from all 149 SARS-Co specimens to determine the 95% LoD of each test (Fig. 1). The molecular POCTs, the Check IT, had 95% LoDs of 34.7 and 39.3 Ct values, respectively, highlighting their abil low quantities of virus. RADTs had 95% LoDs ranging between 25.0 to 28.4 (Table A1	
specimens to determine the 95% LoD of each test (Fig. 1). The molecular POCTs, the Check IT, had 95% LoDs of 34.7 and 39.3 Ct values, respectively, highlighting their abil low quantities of virus. RADTs had 95% LoDs ranging between 25.0 to 28.4 (Table A1 171	
 Check IT, had 95% LoDs of 34.7 and 39.3 Ct values, respectively, highlighting their abil low quantities of virus. RADTs had 95% LoDs ranging between 25.0 to 28.4 (Table A1 	RS-CoV-2 clinical
 low quantities of virus. RADTs had 95% LoDs ranging between 25.0 to 28.4 (Table A1 	, the ID NOW and
171	r ability to detect
172	le A1).
172	
1/5	

175 **Table 2.** Performance characteristics of six COVID-19 point-of-care tests with Pre-Omicron and

176 Omicron samples

		Pre-Omicron			Omicron			
Test	Ct	n Sensitivity (%) 95% Cl		•	n	Sensitivity (%) 95% Cl		P-value
Molecular Tests								
	Overall	55	86	(74–92.4)	94	94.7	(88–97.7)	0.072
ID NOW	<u><</u> 30	30	100	(89–100)	41	100	(91.4–100)	1.000
	>30	25	68	(48–83)	53	90.6	(80–95.9)	0.021*
	Overall	55	98.2	(90.4–99.7)	94	98.9	(94.2–99.8)	1.000
Check IT	<u><</u> 30	30	100	(91.4–100)	41	100	(89–100)	1.000
	>30	25	98.1	(90.1–99.7)	53	99.3	(81–99.3)	0.541
Rapid Antigen D	etection Te	sts						
	Overall	55	64	(50–75)	94	65	(55–74)	1.000
Rapid Response	<u><</u> 30	30	96.7	(83–99.4)	41	97.6	(87–99.6)	1.000
	>30	25	24	(12–43)	53	40	(28–53)	0.210
	Overall	55	51	(38–64)	94	49	(39–59)	0.866
Panbio	<u><</u> 30	30	90.2	(78–96.1)	41	83	(66–92.7)	0.479
	>30	25	17	(9.2–29)	53	12	(4.2–30)	0.742
	Overall	55	49	(36–62)	94	55	(45–65)	0.499
QuickVue	<u><</u> 30	30	87	(70–94.7)	41	92.7	(81–97.5)	0.446
	>30	25	4.0	(0.7–20)	53	26	(16–40)	0.028*
	Overall	55	60	(47–72)	94	47	(37–57)	0.130
Biosensor	<u><</u> 30	30	93.3	(79–98.2)	41	85	(72–93.1)	0.453
		25	20	(8.9–39)	53	17	(9.2–29)	0.759

CI: Confidence Interval; Ct: Cycle Threshold; n: number of SARS-CoV-2 positive samples tested; *:
 significant at P<0.05 for difference in POCT sensitivity between pre-Omicron and Omicron variants using
 Fisher's exact test.

180

181






FIG 1. Probit regression analysis showing the 95% limit of detection of six SARS-CoV-2 point-ofcare tests based on testing outcomes of 149 positive SARS-CoV-2 clinical samples. The cycle threshold of the sample, determined using the RT-qPCR reference standard test result, is plotted against a positive (1) or negative (0) test outcome. The horizontal dashed line indicates the 95% probability of a positive test result while the vertical dashed lines show the 95% limit of detection of each test with shaded areas representing their 95% confidence interval.

Limit of Detection Analysis of POCTs For Pre-Omicron and Omicron Variants

A probit regression model was used to assess if the limit of detection of each test differed when stratified by variant (pre-Omicron vs Omicron). The 95% LoDs of all the POCTs were similar, regardless of the variant, as demonstrated by the sizeable overlap between their confidence intervals (Fig. 2). Due to a poor model fit from lack of false negative results, it was not possible

to determine the 95% LoD of the Check IT for the pre-Omicron and Omicron variant samples,





197	FIG 2. Probit regression analysis with the 95% limit of detection of five SARS-CoV-2 point-of-care
198	tests grouped by variant, based on testing outcomes of 149 positive SARS-CoV-2 clinical
199	samples. Results for pre-Omicron and Omicron samples are represented in blue and red,
200	respectively. The cycle threshold of the sample, determined by the RT-qPCR reference standard
201	test result, is plotted against a positive (1) or negative (0) outcome of the test. The horizontal
202	dashed line indicates the 95% probability of a positive test result while the vertical dashed lines
203	show the 95% limit of detection of each test with shaded areas representing their 95%
204	confidence interval.

DISCUSSION 205

POCTs have been central to the COVID-19 pandemic response, particularly following the 206 appearance of the Omicron variant in late 2021 (2, 3). As new variants emerge, it is important to 207 monitor the performance of POCTs to ensure that test results continue to be reliable. 208 Consequently, the purpose of this study was to evaluate six widely-distributed Health Canada-209 approved POCTs using COVID-19 clinical samples incorporating pre-Omicron and Omicron 210 variants (Alpha to XBB.1.5) to determine if test characteristics differed over time. Overall, our 211 assessment revealed consistent and reliable performance across the variants tested, affirming 212 manufacturer's claims that there is no notable decrease in clinical efficacy. The molecular tests, 213 ID NOW and Check IT, demonstrated the highest sensitivity, and can provide RT-qPCR level 214 quality in settings where centralized testing is unavailable (30). 215

To our knowledge, only two studies, conducted by Stokes et al. (31, 32), have assessed 216 the performance characteristics of the ID NOW in detecting both pre-Omicron and Omicron 217

variants. Per Stokes et al. (31, 32), for symptomatic patients, the ID NOW demonstrated improved 218 sensitivity against Omicron (91.6–96.0%) compared to pre-Omicron (90.0–92.5%). This aligns 219 with the significant increase in test sensitivity against high Ct clinical Omicron samples noted in 220 this study. Potential explanations for this finding may be attributed to various factors including 221 changes in testing procedures over time, patient infection stage, or sample storage and quality. 222 Studies have also reported decreased ID NOW performance with higher Ct samples (33-35). In 223 contrast to traditional RT-qPCR, the ID NOW employs LAMP-based technology that targets a large 224 RNA fragment (>1 kb). Therefore, the device may exhibit reduced sensitivity with fragmented 225 samples from long-term storage, which may be a confounding factor in clinical LAMP validation 226 studies. Additionally, the ID NOW targets RNA-dependant RNA polymerase, an uncommon target 227 among COVID-19 POCTs and RT-qPCR assays. This feature may cause the ID NOW to be affected 228 uniquely by variant mutations as compared to other tests, and the Ct value from the reference 229 assay (targeting N2) may not accurately reflect the abundance of target RNA in each sample. 230

The Check IT has only been independently evaluated in one other publication to date. In a study by Zahavi et al. (8), the device exhibited a sensitivity of 91.1% using samples collected before the emergence of Omicron. This is consistent with the high sensitivity of the Check IT when using both pre-Omicron and Omicron variants observed in this study, with the LoD comparable to that of laboratory-developed qRT-PCR tests.

Using the WHO guidelines for RADT evaluation and clinical relevance (27), at high viral loads (Ct \leq 30) all RADTs met the criteria for acceptable clinical sensitivity (> 80%). In agreement with previous reports and manufacturer claims, test sensitivity of RADTs decreased markedly at

low viral loads (Ct > 30) regardless of variant. It is important to note that comparing LoDs and sensitivity across studies, especially for RADTs, is often challenging due to differences in experimental design. For example, reference Ct values can differ greatly based on methodology and gene target. Recently, media reported on possible issues in the design of the BTNX validation studies used for regulatory approval (36); however, this study corroborates manufacturer claims and has identified no appreciable differences in analytical test performance between the BTNX and the other RADTs investigated in this study.

A meta-analysis by Mohammadie et al. (37) on RADT performance revealed a pooled sensitivity of 67% and a non-significant reduction in overall RADT sensitivity against Omicron. While these general trends provide valuable insights into overall RADT performance, the diversity of targets needs to be considered. Although as a group RADTs demonstrate compatibility with emerging variants, each test recognizes unique viral epitopes and should also be investigated individually.

The QuickVue RADT showed significantly improved sensitivity against low viral load 252 Omicron samples, consistent with findings by Sugiharto et al. (24); however, work by Rao et al. 253 (38) showed no change in QuickVue sensitivity against Omicron variants. All other RADTs 254 evaluated in this study showed no significant change in test performance against Omicron 255 variants. Previous studies evaluating RADTs have consistently reported similar or reduced clinical 256 sensitivity with Omicron as compared to early pandemic variants (21, 37, 39). For example, 257 multiple studies investigating the Abbott Panbio using cultured virus (40) and clinical samples 258 (23, 41) have shown no sensitivity loss against Omicron. Alternatively, work by Bekliz al. (19) 259

reported a significant reduction in Panbio sensitivity with Omicron BA.1 compared to Delta.
 Biosensor demonstrated comparable performance with cultured Omicron variants (40, 42), but
 in other studies exhibited reduced clinical sensitivity (19, 20). To our knowledge, this is the first
 study investigating the sensitivity of the BTNX Rapid Response against multiple SARS-CoV-2
 variants including Omicron.

A limitation of this study is the use of anonymized remnant clinical samples instead of clinical patient swabs. The use of clinical swabs was not feasible as multiple variants investigated in this study are no longer circulating and this study required a large number of paired samples to evaluate multiple technologies. Due to the anonymization of samples used in this study, we were not able to incorporate information that may affect test sensitivity or specificity, such as vaccination status or patient clinical presentation, into our analyses (13, 14, 39).

Unlike many studies that primarily focused on comparing BA.1 exclusively with the Delta variant, our research included a representative range of both pre-Omicron and Omicron subvariants (Alpha to XBB.1.5). Considering both the overall sensitivity and limit of detection, we observed no decline in test performance against Omicron variants; however, it is important to continue to evaluate these parameters as new variants emerge. Sustained post-market surveillance efforts are required to proactively identify issues that could impact decentralized testing for COVID-19.

278

280 ETHICS APPROVAL

281	No ethics were required under Article 2.4 and Article 2.5 of the Tri-Council Policy
-----	---

- 282 Statement Ethical Conduct for Research Involving Humans (26) since remnant clinical specimens
- were used for the purpose of quality assurance.

284 FUNDING

This research was funded by the Public Health Agency of Canada.

286 CONFLICTS OF INTEREST

The authors declare no conflict of interest.

288			
289			
290			
291			
292			
293			
294			
295			

296 SUPPLEMENTAL MATERIAL

297	Table A1. Probit regression calculated 95% Limit of Detection of six COVID-19 point-of-care tests
298	based on 149 SARS-CoV-2 positive clinical samples.

Test		Predicted 9	95% L <mark>oD (C</mark>	t) 95% Cl ¹		
Test	All (n=149)		Pre-omicron (n=54)		Omicron (n=95)	
Molecular Tests						
ID NOW	34.7	(33.1, 36.4)	34.6	(32.6, 36.6)	35.8	(33.4, 38.2)
Check IT	39.3	(37.2, 41.4)		N/A ²	38.7	(35.6, 41.8)
Rapid Antigen Tes	ts					
Panbio	26.3	(24.9, 27.6)	25.9	(23.8, 27.9)	26.6	(24.9, 28.4)
Rapid Response	28.4	(27.0, 29.7)	28.7	(26.8, 30.7)	28.2	(26.4, 30.1)
QuickVue	26.6	(25.2, 28.0)	25.4	(23.1, 27.6)	27.7	(26.1, 29.3)
Biosensor	25.0	(23.2, 26.8)	26.1	(23.4, 28.8)	24.4	(21.9, 26.9)

¹95% Wald confidence intervals; ²N/A since insufficient data, n - number of SARS-CoV-2 positive samples.

300 **REFERENCES**

- 1. Zhang Y, Garner R, Salehi S, Rocca M, Duncan D. 2022. Molecular and antigen tests, and sample types for diagnosis of COVID-19: a review. Future Virol 17:675-85.
- Buchta C, Gorzer I, Chiba P, Camp JV, Holzmann H, Puchhammer-Stockl E, Mayerhofer M, Muller
 MM, Aberle SW. 2021. Variability of cycle threshold values in an external quality assessment
 scheme for detection of the SARS-CoV-2 virus genome by RT-PCR. Clin Chem Lab Med 59:987 994.
- 307 3. Vogel L. 2022. An early look at Omicron. CMAJ 194:E58.
- Temsah MH, Alenezi S, Alarabi M, Aljamaan F, Alhasan K, Assiri R, Bassrawi R, Alshahrani F,
 Alhaboob A, Alaraj A, Alharbi NS, Alrabiaah A, Halwani R, Jamal A, Abdulmajeed N, Alfarra L,
 Almashdali W, Al-Eyadhy A, AlZamil F, Alsubaie S, Barry M, Memish ZA, Al-Tawfiq JA. 2022.
 Healthcare Workers' SARS-CoV-2 Omicron Variant Uncertainty-Related Stress, Resilience, and
 Coping Strategies during the First Week of the World Health Organization's Alert. Int J Environ
- 313Res Public Health 19.
- Singhal T. 2022. The Emergence of Omicron: Challenging Times Are Here Again! Indian J Pediatr
 89:490-496.
- Mahase E. 2021. Covid-19: Hospital admission 50-70% less likely with omicron than delta, but
 transmission a major concern. BMJ 375:n3151.
- 3187.Government of Canada. 2023. Interim order respecting the importation and sale of medical319devices for use in relation to COVID-19. https://www.canada.ca/en/health-320canada/services/drugs-health-products/drug-products/announcements/interim-order-321importation-sale-medical-devices-covid-19.html. Accessed 2023-09-04.
- 8. Zahavi M, Rohana H, Azrad M, Shinberg B, Peretz A. 2022. Rapid SARS-CoV-2 Detection Using the Lucira Check It COVID-19 Test Kit. Diagnostics (Basel) 12.
- 9. Chu VT, Schwartz NG, Donnelly MAP, Chuey MR, Soto R, Yousaf AR, Schmitt-Matzen EN, Sleweon
- 325 S, Ruffin J, Thornburg N, Harcourt JL, Tamin A, Kim G, Folster JM, Hughes LJ, Tong S, Stringer G,

Albanese BA, Totten SE, Hudziec MM, Matzinger SR, Dietrich EA, Sheldon SW, Stous S, McDonald 326 EC, Austin B, Beatty ME, Staples JE, Killerby ME, Hsu CH, Tate JE, Kirking HL, Matanock A, Team C-327 HT. 2022. Comparison of Home Antigen Testing With RT-PCR and Viral Culture During the Course 328 of SARS-CoV-2 Infection. JAMA Intern Med 182:701-709. 329 10. Leitao IC, Calil PT, Galliez RM, Moreira FRR, Mariani D, Castineiras ACP, da Silva GPD, Maia RA, 330 Correa IA, Monteiro FLL, de Souza MRM, Goncalves CCA, Higa LM, de Jesus Ribeiro L, Fonseca 331 VWP, Bastos VC, Voloch CM, Faffe DS, da Costa Ferreira O, Jr., Tanuri A, Castineiras T, da Costa LJ, 332 on the behalf of the U-CW. 2021. Prolonged SARS-CoV-2 Positivity in Immunocompetent 333 Patients: Virus Isolation, Genomic Integrity, and Transmission Risk. Microbiol Spectr 9:e0085521. 334 Bar-On YM, Flamholz A, Phillips R, Milo R. 2020. SARS-CoV-2 (COVID-19) by the numbers. Elife 9. 11. 335 12. Dinnes J, Sharma P, Berhane S, van Wyk SS, Nyaaba N, Domen J, Taylor M, Cunningham J, 336 Davenport C, Dittrich S, Emperador D, Hooft L, Leeflang MM, McInnes MD, Spijker R, Verbakel JY, 337 Takwoingi Y, Taylor-Phillips S, Van den Bruel A, Deeks JJ, Cochrane C-DTAG. 2022. Rapid, point-of-338 care antigen tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 339 7:CD013705. 340 Parvu V, Gary DS, Mann J, Lin YC, Mills D, Cooper L, Andrews JC, Manabe YC, Pekosz A, Cooper 13. 341 CK. 2021. Factors that Influence the Reported Sensitivity of Rapid Antigen Testing for SARS-CoV-342 2. Front Microbiol 12:714242. 343 14. Robinson ML, Mirza A, Gallagher N, Boudreau A, Garcia Jacinto L, Yu T, Norton J, Luo CH, Conte 344 A, Zhou R, Kafka K, Hardick J, McManus DD, Gibson LL, Pekosz A, Mostafa HH, Manabe YC. 2022. 345 Limitations of Molecular and Antigen Test Performance for SARS-CoV-2 in Symptomatic and 346 Asymptomatic COVID-19 Contacts. J Clin Microbiol 60:e0018722. 347 15. Patriquin G, Davidson RJ, Hatchette TF, Head BM, Mejia E, Becker MG, Meyers A, Sandstrom P, 348 Hatchette J, Block A, Smith N, Ross J, LeBlanc JJ. 2021. Generation of False-Positive SARS-CoV-2 349 Antigen Results with Testing Conditions outside Manufacturer Recommendations: A Scientific 350 Approach to Pandemic Misinformation. Microbiol Spectr 9:e0068321. 351 Li X, Tam AR, Chu WM, Chan WM, Ip JD, Chu AW, Abdullah SMU, Yip CC, Chan KH, Wong SS, 16. 352 Cheng VC, Yuen KY, Hung IF, To KK. 2022. Risk Factors for Slow Viral Decline in COVID-19 Patients 353 during the 2022 Omicron Wave. Viruses 14. 354 17. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, Subramoney K, Makatini Z, 355 Moyo S, Amoako DG, Baxter C, Althaus CL, Anyaneji UJ, Kekana D, Viana R, Giandhari J, Lessells 356 RJ, Maponga T, Maruapula D, Choga W, Matshaba M, Mbulawa MB, Msomi N, consortium N-S, 357 Naidoo Y, Pillay S, Sanko TJ, San JE, Scott L, Singh L, Magini NA, Smith-Lawrence P, Stevens W, Dor 358 G, Tshiabuila D, Wolter N, Preiser W, Treurnicht FK, Venter M, Chiloane G, McIntyre C, O'Toole A, 359 Ruis C, Peacock TP, Roemer C, Kosakovsky Pond SL, Williamson C, Pybus OG, Bhiman JN, Glass A, 360 et al. 2022. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med 361 28:1785-1790. 362 18. U.S. Food & Drug Administration. 23-09-28 2023. SARS-CoV-2 Viral Mutations: Impact on 363 COVID-19 Tests. https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-364 devices/sars-cov-2-viral-mutations-impact-covid-19-tests. Accessed 2023-11-05. 365 19. Bekliz M, Adea K, Puhach O, Perez-Rodriguez F, Marques Melancia S, Baggio S, Corvaglia AR, 366 Jacquerioz F, Alvarez C, Essaidi-Laziosi M, Escadafal C, Kaiser L, Eckerle I. 2022. Analytical 367 Sensitivity of Eight Different SARS-CoV-2 Antigen-Detecting Rapid Tests for Omicron-BA.1 Variant. 368 Microbiol Spectr 10:e0085322. 369 20. Bayart JL, Degosserie J, Favresse J, Gillot C, Didembourg M, Djokoto HP, Verbelen V, Roussel G, 370 Maschietto C, Mullier F, Dogne JM, Douxfils J. 2022. Analytical Sensitivity of Six SARS-CoV-2 Rapid 371 372 Antigen Tests for Omicron versus Delta Variant. Viruses 14.

Osterman A, Badell I, Basara E, Stern M, Kriesel F, Eletreby M, Oztan GN, Huber M, Autenrieth H,
Knabe R, Spath PM, Muenchhoff M, Graf A, Krebs S, Blum H, Durner J, Czibere L, Dachert C,
Kaderali L, Baldauf HM, Keppler OT. 2022. Impaired detection of omicron by SARS-CoV-2 rapid
antigen tests. Med Microbiol Immunol 211:105-117.
Gourgeon A, Soulier A, Audureau E, Khouider S, Galbin A, Langlois C, Bouvier-Alias M, Bodriguez

- Gourgeon A, Soulier A, Audureau E, Khouider S, Galbin A, Langlois C, Bouvier-Alias M, Rodriguez
 C, Chevaliez S, Pawlotsky JM, Fourati S. 2022. Performance of 22 Rapid Lateral Flow Tests for
 SARS-CoV-2 Antigen Detection and Influence of "Variants of Concern": Implications for Clinical
 Use. Microbiol Spectr 10:e0115722.
- de Michelena P, Torres I, Ramos-Garcia A, Gozalbes V, Ruiz N, Sanmartin A, Botija P, Poujois S,
 Huntley D, Albert E, Navarro D. 2022. Real-life performance of a COVID-19 rapid antigen
 detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the
 Omicron variant. J Infect 84:e64-e66.
- Sugiharto VA, Gatrell SK, Chen HW, Blazek GR, Cherry AM, Schilling M. 2023. Performance
 Evaluation of Five Rapid At-Home COVID-19 Antigen Tests against the Omicron Variant. Microbiol
 Spectr 11:e0228622.
- Badnjevic A, Pokvic LG, Deumic A, Becirovic LS. 2022. Post-market surveillance of medical
 devices: A review. Technol Health Care 30:1315-1329.
- 26. Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of
 Canada, and Social Sciences and Humanities Research Council of Canada. 2022. Tri-Council Policy
 Statement: Ethical Conduct for Research Involving Humans.
- Organization WH. 2020. Target product profiles for priority diagnostics to support response to
 the COVID-19 pandemic v.1.0.
- Zacharioudakis IM, Prasad PJ, Zervou FN, Basu A, Inglima K, Weisenberg SA, Aguero-Rosenfeld
 ME. 2021. Association of SARS-CoV-2 Genomic Load with Outcomes in Patients with COVID-19.
 Ann Am Thorac Soc 18:900-903.
- 39829.Clinical and Laboratory Standards Institute. 2023. Evaluation of Qualitative, Binary Output399Examination Performance. Clinical and Laboratory Standards Institute,
- 40030.Health Canada. 2021. Pan-Canadian COVID-19 Testing and Screening Guidance: Technical401guidance and implementation plan.
- Stokes W, Berenger BM, Singh T, Adeghe I, Schneider A, Portnoy D, King T, Scott B, Pabbaraju K,
 Shokoples S, Wong AA, Gill K, Turnbull L, Hu J, Tipples G. 2021. Acceptable performance of the
 Abbott ID NOW among symptomatic individuals with confirmed COVID-19. J Med Microbiol 70.
- 32. Stokes W, Venner AA, Buss E, Tipples G, Berenger BM. 2023. Evaluation of the ID NOW among
 symptomatic individuals during the Omicron wave. J Med Microbiol 72.
- 33. Basu A, Zinger T, Inglima K, Woo KM, Atie O, Yurasits L, See B, Aguero-Rosenfeld ME. 2020.
 Performance of Abbott ID Now COVID-19 Rapid Nucleic Acid Amplification Test Using
 Nasopharyngeal Swabs Transported in Viral Transport Media and Dry Nasal Swabs in a New York
 City Academic Institution. J Clin Microbiol 58.
- 34. Smithgall MC, Scherberkova I, Whittier S, Green DA. 2020. Comparison of Cepheid Xpert Xpress
 and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2. J Clin Virol
 128:104428.
- 41435.Mitchell SL, George KS. 2020. Evaluation of the COVID19 ID NOW EUA assay. J Clin Virol415128:104429.
- 36. Sonntag P. 23-12-22 2023. COVID test supplier received billions in pandemic contracts after
 submitting edited results, *on* Global News, a division of Corus Entertainment Inc.
 https://globalnews.ca/news/10183219/covid-test-supplier-canada/. Accessed 23-12-22.

419	37.	Mohammadie ZE, Akhlaghi S, Samaeinasab S, Shaterzadeh-Bojd S, Jamialahmadi T, Sahebkar A.
420		2023. Clinical performance of rapid antigen tests in comparison to RT-PCR for SARS-COV-2
421		diagnosis in Omicron variant: A systematic review and meta-analysis. Rev Med Virol 33:e2428.
422	38.	Rao A, Westbrook A, Bassit L, Parsons R, Fitts E, Greenleaf M, McLendon K, Sullivan JA, O'Sick W,
423		Baugh T, Bowers HB, Frank F, Wang E, Le M, Frediani J, Roychoudhury P, Greninger AL, Jerris R,
424		Pollock NR, Ortlund EA, Roback JD, Lam WA, Piantadosi A. 2023. Sensitivity of rapid antigen tests
425		against SARS-CoV-2 Omicron and Delta variants. J Clin Microbiol doi:10.1128/jcm.00138-
426		23:e0013823.
427	39.	Krenn F, Dachert C, Badell I, Lupoli G, Oztan GN, Feng T, Schneider N, Huber M, Both H, Spath
428		PM, Muenchhoff M, Graf A, Krebs S, Blum H, Durner J, Czibere L, Kaderali L, Keppler OT, Baldauf
429		HM, Osterman A. 2023. Ten rapid antigen tests for SARS-CoV-2 widely differ in their ability to
430		detect Omicron-BA.4 and -BA.5. Med Microbiol Immunol 212:323-337.
431	40.	Mackenzie C, Batty M, Papadakis G, Stevens L, Yoga Y, Taiaroa G, Stefanatos H, Savic I, Tran T,
432		Deerain J, Prestedge J, Druce J, Caly L, Williamson DA. 2022. Analytical Sensitivity of Lateral Flow
433		Devices against SARS-CoV-2 Omicron Subvariants BA.4, BA.5, and BA.2.75. J Clin Microbiol
434		60:e0109722.
435	41.	Jungnick S, Hobmaier B, Paravinja N, Mautner L, Hoyos M, Konrad R, Haase M, Baiker A, Eberle
436		U, Bichler M, Treis B, Okeyo M, Streibl B, Wimmer C, Hepner S, Sprenger A, Berger C, Weise L,
437		Dangel A, Ippisch S, Jonas W, Wildner M, Liebl B, Ackermann N, Sing A, Fingerle V, Bavarian S-C-
438		PHLT. 2023. Analysis of seven SARS-CoV-2 rapid antigen tests in detecting omicron (B.1.1.529)
439		versus delta (B.1.617.2) using cell culture supernatants and clinical specimens. Infection 51:239-
440		245.
441	42.	Deerain J, Druce J, Tran T, Batty M, Yoga Y, Fennell M, Dwyer DE, Kok J, Williamson DA. 2022.
442		Assessment of the Analytical Sensitivity of 10 Lateral Flow Devices against the SARS-CoV-2
443		Omicron Variant. J Clin Microbiol 60:e0247921.